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current was caused by activation of N-methyl-d-aspartateInvolvement of voltage- and ligand-gated Ca2 channels in the
(NMDA) receptor-associated ion channels. Low (mol/L) con-neuroexcitatory and synergistic effects of putative uremic neu-
centrations of spermine potentiated guanidinosuccinate-evokedrotoxins.
current through the action of spermine on the polyamine bind-Background. Renal failure has been viewed as a state of cell-
ing site of the NMDA receptor complex, whereas current evokedular calcium toxicity due to the retention of small fast-acting
by high (mmol/L) concentrations of spermine alone involvedmolecules. We have tested this hypothesis and identified poten-
direct activation of voltage-gated Ca2 channels. Finally, intra-tially neuroexcitatory compounds among a number of putative
cerebroventricular administration of 0.25 mol/L spermine po-uremic neurotoxins by examining the acute in vitro effects of
tentiated clonic convulsions induced by guanidinosuccinate.these compounds on cultured central neurons. The in vitro
These neuroexcitatory and synergistic effects of guanidinosuc-neuroexcitatory and synergistic effects of guanidinosuccinate
cinate and spermine could take place at pathophysiologic con-and spermine were also examined in vivo.
centrations.Methods. The acute effects of 17 candidate uremic neurotox-
Conclusion. The observed in vitro and in vivo effects of ure-ins on murine spinal cord neurons in primary dissociated cell
mic retention solutes suggest that the identified compoundsculture were investigated using the tight-seal whole-cell re-
could play a significant role in uremic pathophysiology. Somecording technique. The compounds studied comprised low-molec-
of the compounds tested displayed in vitro and in vivo neuro-ular-weight solutes like urea, indoles, guanidino compounds,
excitatory effects that were mediated by ligand- and voltage-polyamines, purines and phenoles, homocysteine, orotate, and
gated Ca2 channels. The findings suggest a mechanism for themyoinositol. Currents evoked by these compounds were fur-
involvement of calcium toxicity in the central nervous systemther examined using various ligand- and voltage-gated ion
complications in renal failure with particular reference to gua-channel blockers. The acute in vivo effects of guanidinosucci-
nidinosuccinate and spermine.nate and spermine were behaviorally assessed following their
injection in mice.
Results. It was shown that 3-indoxyl sulfate, guanidinosucci-
nate, spermine, and phenol evoked significant whole-cell cur- Renal insufficiency leading to uremia has been knownrents. Inward whole-cell current evoked by 3-indoxyl sulfate
to affect almost all bodily functions, but especially brainwas not blocked by any of the applied ligand- or voltage-gated
physiology appears to be vulnerable to uremic toxicityion channel blockers, and the compound appeared to influence
miscellaneous membrane ionic conductances, probably involv- [1–4]. Unfortunately, some of the manifestations of the
ing voltage-gated Ca2 channels as well. Phenol-evoked out- resulting uremic encephalopathy, which include cogni-
ward whole-cell currents were at least partly due to the activa- tive and attentional impairments, lowered level of arousal,tion of voltage-gated K channels, but may also involve a
convulsions, and coma, can only be incompletely re-variety of other ionic conductances. On the other hand, inward
versed by treatment [1, 5]. It has long been establishedwhole-cell currents evoked by guanidinosuccinate and sperm-
ine were shown to be due to specific interaction with voltage- that renal failure can have irreversible or even degenera-
and ligand-gated Ca2 channels. Guanidinosuccinate-evoked tive effects on the brain [6], and the developing brain
appears to be particularly sensitive to uremic neurotoxic-
ity [7–10].Key words: uremia, guanidines, polyamines, NMDA receptors, calcium
channels. Despite many years of research, the mechanisms of
uremic neurotoxicity are only partially understood [11].Received for publication May 24, 2002
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fast-acting molecules [12]. Renal insufficiency leads to solution containing 140 mmol/L NaCl, 3.5 mmol/L KCl,
1 mmol/L CaCl2, 10 mmol/L HEPES, 5 mmol/L glucose,the accumulation of a large number of compounds, col-
lectively known as uremic retention solutes, in biologic 103 mmol/L glycine, and 0.5  103 mmol/L TTX (pH
adjusted to 7.4 with NaOH and osmolarity to 315 tofluids and tissues. Many of these uremic retention sol-
utes, which accumulate as a direct or indirect conse- 320 mosmol/L with sucrose). Pipette solution contained
30 mmol/L KCl, 110 mmol/L KOH, 110 mmol/L K-aspar-quence of deficient renal clearance, have been proposed
as possible uremic toxins [11, 13, 14]. The identification tate, 10 mmol/L HEPES, 2 mmol/L ethylene glycol tetra-
acetic acid (EGTA), 5 mmol/L Na-ATP, 2 mmol/LMgCl2,and (patho)physiologic study of putative uremic toxins
may help to further our understanding of the uremic 1 mmol/L CaCl2, 0.1 cyclic adenosine monophosphate
(cAMP) (adjusted to pH 7.4 with KOH and to 315 tosyndrome, introduce alternative marker molecules for
uremic retention and treatment efficacy, and direct the 320 mosmol/L with sucrose). A fast-perfusion system
was used for the application of chemicals to the cells.pursuit of novel therapeutic avenues.
The compounds studied in this report were selected The flow outlet of the system was placed within 0.5 mm
of the spinal neuron, and air pressure was applied toas candidate uremic neurotoxins and comprise some of
the smaller molecules like urea, indoles, guanidino com- obtain a flow rate of 1.2 to 1.3 mL/min. All products
were purchased from Sigma Chemicals (Sigma-Aldrich,pounds, polyamines, purines and phenoles, homocys-
teine, orotate, and myoinositol [11, 13, 14]. This study is Bornem, Belgium) and dissolved in bath solution; pH
was readjusted to 7.4 with NaOH where necessary.actually the first large-scale screening of uremic retention
solutes for their possible neuroexcitatory effects. The
Whole-cell current recordingselected solutes were applied to mouse spinal cord neu-
Current recordings were made in whole-cell mode byrons in primary dissociated cell cultures. The acute effect
using a single-patch pipette [18]. Patch-pipettes with aof such an application on these neurons was examined
resistance of 3 to 5 Mwere pulled from glass capillariesusing the tight-seal whole-cell recording technique [15].
(Jencons, H10/15, Bedfordshire, UK) with a P-87 Brown-In compounds that evoked distinct whole-cell currents,
Flaming horizontal micropipette puller (Sutter Instru-electrophysiologic, and neuropharmacologic manipula-
ments, Novato, CA, USA), and heat-polished. Pipettestions were used to investigate the nature of the evoked
were positioned with a Narishige micromanipulator (Lon-current. Ligand-gated channel inhibitors used for this
don, UK) and visualized with an inverted microscopeincluded Mg2 and 2-amino-4-methyl-5-phosphono-3-pen-
(Zeiss IM35, Belgium). After establishing the whole-tenoate (4-methyl APPA), respectively, as noncompeti-
cell configuration, cells were clamped at a membranetive and competitive antagonists at N-methyl-d-aspartate
potential of60 mV except were mentioned differently.(NMDA)-type glutamate receptors, 6-cyano-7-nitro-
Whole-cell currents were measured with the Axoclamp-quinoxaline-2, 3-dione (CNQX) as a mixed glutamate re-
2A amplifier (Axon Instruments, Union City, CA, USA),ceptor antagonist, ifenprodil as an antagonist at the polya-
equipped with the HS-2L headstage, in the discontinuousmine site of the NMDA receptor, and bicuculline as a
single-electrode voltage clamp mode with optimal sam--aminobutyrate type A (GABAA) receptor antagonist.
pling rate of 2 to 3 kHz confirmed on a second oscillo-Voltage-gated ion channel modifying agents [16] in-
scope.cluded Ba2 as a nonspecific K channel inhibitor, Ni 2
To compensate for differences in cell size, some of theas an L-type Ca2 channel inhibitor, Cd2 as a mixed Ca2
measured currents were scaled to cell capacitance. Achannel inhibitor, tetrodotoxin (TTX) as a specific Na
5 V hyperpolarizing voltage-step of 20 mseconds waschannel inhibitor, and tetraethylammonium (TEA) as a
applied, and cell capacitance was calculated by integra-specific K channel inhibitor. Finally, two of the identi-
tion of the resulting capacitive transient. Data were storedfied agents were applied to mice to assess their in vivo
via a TL-1-125 Labmaster (Mentor, OH, USA) interfaceneuroexcitatory and possibly synergistic effects.
on a IBM-compatible computer and analyzed by
pClamp6 (Axon Instruments, Union City, CA, USA)METHODS
and conventional software. Curve fitting and error calcu-
Cell cultures and chemicals lations were done with Sigmaplot software (SPSS Sci-
The effects of different uremic retention solutes were ence, Erkrath, Germany).
studied in cultured mouse spinal cord neurons. Spinal
In vivo effects of guanidinosuccinate and sperminecord cells were obtained from primary cultures of dissoci-
ated spinal cords of 12- to 14-day-old mouse embryos For the study of the in vivo effects of guanidinosucci-
nate and spermine injection, male Swiss mice (25 g, meanaccording to a method modified from Ransom, Bullock,
and Nelson [17]. After dissociation, the cells were kept body weight) were administered intraperitoneal guani-
dinosuccinate injections with or without spermine pre-in culture for 4-6 weeks before use.
All recordings were performed at room temperature. treatment. Mice were observed for 60 minutes after guani-
dinosuccinate injection. Spermine, 0.25 mol, was appliedSpinal neurons were continuously superfused with bath
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Table 1. Absolute and relative whole-cell currents evoked by
uremic retention solutes (5 mmol/L concentrations) on
five similar-sized spinal cord neurons
Whole-cell Relative whole-cell
Compound current pA current pA/pF
Urea 4.92.8 0.050.03
Indoles
l-tryptophan 6.43.4 0.060.04
Indole-3-acetate 7.62.5 0.0670.025
3-Indoxyl sulfate 26843 3.90.7a
Guanidino compounds
Creatinine 114 0.170.06Fig. 1. Typical current tracings derived from two spinal cord cells dur-
Guanidine 106 0.140.08ing the application of uremic retention solutes from each of the chemical
Methylguanidine 24 0.030.05groups tested. Holding potential (Vh) was60 mV. All compounds were
Guanidinosuccinate 478141 4.20.8aapplied for 5 seconds in a concentration of 5 mmol/L (indicated as hori-
Polyamineszontal bars above the current tracings), except reference compounds
Spermine 10520 1.60.4al-aspartate, which was applied in a concentration of 20 mol/L. Scale
Spermidine 6115 0.960.28bars are shown on the top left. Abbreviations are: Asp, l-aspartate; HC,
PurinesDL-homocysteine; Trp, L-tryptophan; OA, orotate; MI, myoinositol;
Xanthine 3.92.1 0.0570.029GSA, guanidinosuccinate; IAA, indole-3-acetate; Cresol, p-cresol; HX,
Hypoxanthine 3311 0.300.12hypoxanthine; HA, hippurate; and Sp, spermine.
Hippurate 318 0.280.07
Phenoles
p-Cresol 8149 0.70.3by intracerebroventricular injection 15 minutes prior to
Phenol 19847 2.60.5athe guanidinosuccinate injection. Doses and administra- Miscellaneous
tion routes used in these protocols were based on previ- DL-Homocysteine 419 0.530.11
Orotate 93 0.110.05ous and preliminary experiments, and in accordance with
Myoinositol 9.61.6 0.1270.018available literature [19]. Guanidinosuccinate and sper-
All data are mean  SEM.mine were dissolved in phosphate-buffered saline (PBS)
a Significantly different from relative current evoked by urea (Dunnett multiple
(pH was readjusted with NaOH in the guanidinosucci- comparison test; P  0.05)
nate solutions). Spermine wa intracerebroventricular in-
jected in a volume of 5L and at an injection rate of 1L/
5 seconds (needle was kept in place for an additional 15 concentrations. Figure 1 shows whole-cell current trac-
seconds). Control animals received intracerebroventric- ings recorded from two similar-sized cells clamped at
ular saline injections. Injection and observation methods Vh 	 60 mV. Reference compound l-aspartate was ap-
were as described previously [19]. Clonic seizures of stage 1 plied in a concentration of 20 mol/L, and evoked an
were defined as generalized clonic convulsions without inward whole-cell current in these cells of approximately
loss of righting reflex. These seizures would appear as run- 350 pA in amplitude (Fig. 1, top tracing). A few of the
ning or jumping fits, automatisms, or clonic movements candidate toxins evoked discernible inward currents.
of more than one limb. Stage 2 seizures were more vigor-
These included, in decreasing order of potency, guani-ous and sustained clonic convulsions with loss of righting
dinosuccinate (approximately 400 pA), spermine (202 pA),reflex. These seizures would appear as rolling or fast cir-
homocysteine (62 pA), and hypoxanthine (42 pA). Allcling and falling with clonic contraction of limb or trunk
other compounds evoked no or very small currentsmuscles. Mice displaying stage 2 seizures would often lie
(20 pA in amplitude). Notably, p-cresol caused an out-on their backs, making fast waving or grasping move-
ward current in these cells of approximately 90 pA inments with hands and feet. Convulsive dose in 50% of
amplitude.the animals (CD50) and 95% confidence interval were
determined according to Weil [20]; statistical significance In a first survey, each of the studied uremic solutes
of differences between CD50 values was assessed ac- was applied in a concentration of 5 mmol/L to five differ-
cording to Litchfield and Wilcoxon [21]. All animals re- ent cells, and holding currents during these applications
ceived local anesthesia (50 L 1% xylocaine solution) were compared to the current during the application
prior to intracerebroventricular injection, and protocols of urea (Table 1). Although cells of similar sizes were
were in strict agreement with institutional ethical review selected, corrections were made for differences in cell
standards. size by dividing each current by its respective cell capaci-
tance. Mean cell capacitance (SEM) in these cells was
RESULTS 107  13 pF (N 	 6). One-way ANOVA (analysis of
Application of uremic retention solutes to variance) revealed a highly significant difference in mean
spinal neurons relative holding current between the different com-
pounds (P  0.001). Multiple comparison versus ureaUremic retention solutes from each of the tested groups
were applied to cultured spinal cord neurons in 5 mmol/L showed a significant difference for 3-indoxyl sulfate, gua-
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Fig. 2. Inward whole-cell currents evoked by 3-indoxyl sulfate (IS).
(A ) The current tracing shows reversible attenuation of the indoxyl
sulfate–evoked current by 5 mmol/L Ba2 in a cell with Vh 	 60 m.
Indoxyl sulfate was applied for 5 seconds in a concentration of 5 mmol/L
(indicated as horizontal bars above the current tracings). Scale bars are
shown on the left. (B ) The effects of five different ion channel blockers
were studied on indoxyl sulfate–evoked current. The following concen-
trations were used: 5 mmol/L Ba2; 5 mmol/L Ni2; 200 mol/L Cd2;
30 mol/L tetrodotoxin (TTX); and 10 mmol/L tetraethylammonium
Fig. 3. Whole-cell currents evoked by 5 mmol/L p-cresol and 5 mmol/L(TEA). All data are mean relative currents of six cells with SEMs (error
DL-homocysteine, and the effect of blocking agents. (A) A typical re-bars). *Significantly different from current evoked by 5 mmol/L IS
cording in a neuron clamped at –60 mV shows reversal of the p-cresol–(Dunnett multiple comparison test; P  0.05).
evoked outward whole-cell current by co-application of 5 mmol/L Ba2
or 10 mmol/L tetraethylammonium (TEA). (B) Inward whole-cell cur-
rent evoked by DL-homocysteine is blocked by 10 mol/L 4-methyl
APPA (APPA) or 500 mol/L Mg2, but not by 100 mol/L bicucul-
line (Bic).nidinosuccinate, spermine, and phenol (Dunnett test;
Table 1).
The indole compound 3-indoxyl sulfate evoked a mean
line, Ni2, Cd2, TTX, and ifenprodil (not shown). In-inward whole-cell current (SEM) of 268  43 pA in
ward currents evoked by 5 mmol/L DL-homocysteineamplitude (see also Fig. 2A). Application of 100 mol/L
were blocked by application of the NMDA antagonistsbicuculline, 500 mol/L Mg2, or [10 mol/L 4-methyl
4-methyl APPA or Mg2, whereas the GABAA antago-APPA 10 M CNQX] did not affect the current evoked
nist bicuculline had no effect on this current (Fig. 3B).by this compound, indicating that it is not mediated by
ligand-gated channels of the GABAA, 
-amino-3-hydroxy-
Inward whole-cell currents evoked by5-methyl-9-isoxazole propionic acid (AMPA), or NMDA
guanidinosuccinate and polyaminestype. Also, application of 10 mol/L ifenprodil did not
Comparison of four uremic guanidino compounds,affect the 3-indoxyl sulfate current. In a second experi-
namely creatinine, guanidine, methylguanidine, and gua-ment (six cells), the effects of five different ion channel
nidinosuccinate, showed that only guanidinosuccinateblockers was studied on 3-indoxyl sulfate–evoked cur-
significantly evoked (inward) whole-cell current in theserent (Fig. 2B). One-way repeated-measures ANOVA
neurons (Table 1). Two other metabolically related gua-revealed a highly significant difference between the cur-
nidino compounds, namely -guanidinopropionate andrents (P  0.001). Multiple comparison showed that
guanidinoacetate, also evoked inward current (Fig. 4). Inapplication of 5 mmol/L Ba2 or 200 mol/L Cd2 sig-
a series of eight neurons, 5 mmol/L guanidinosuccinatenificantly decreased 3-indoxyl sulfate–evoked current
evoked a mean inward current ( SEM) of 577 119 pA(Dunnett test; Fig. 2B).
(7.5  1.5 pA/pF) in amplitude; 5 mmol/L -guanidino-Outward whole-cell currents evoked by 5 mmol/L
propionate evoked a current of 399  78 pA (5.3  1.0p-cresol were reversed by the application of 5 mmol/L
pA/pF) and 5 mmol/L guanidinoacetate evoked a currentBa2 or 10 mmol/L TEA indicating that the current is
of 421  80 pA (5.5  1.0 pA/pF). -Guanidinobutyricat least partly due to activation of K ion channels
acid evoked a slight outward current (Fig. 4A). Although(Fig. 3A). Blocking agents that did not appear to affect
this current included 4-methyl APPA, CNQX, bicucul- the currents evoked by -guanidinopropionate or gua-
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Fig. 4. Whole-cell currents evoked by uremic guanidines and the effect
of N-methyl-D-aspartate (NMDA) antagonists. (A) These typical cur-
rent tracings were recorded at Vh 	60 mV during the application of
reference compound of 20mol/L l-aspartate, and 5 mmol/L concentra-
tions of six different guanidino compounds. (B) Inward current evoked
by five mmol/L guanidinosuccinate (GSA) is reversibly blocked by
500 mol/L Mg2, but this antagonist did not affect the current evoked
Fig. 5. Polyamines spermine and spermidine evoke inward whole-cellby -guanidinopropionate (GPA) or guanidinoacetate (GAA). (C )
currents in concentration-dependent fashion. (A) A typical current trac-Both the noncompetitive NMDA antagonist Mg2 (500mol/L) and the
ing shows the dose-dependent increase in the amplitude of the spermine-competitive antagonist 4-methyl APPA (10 mol/L) reversibly blocked
evoked current. Spermine was applied for 5 seconds in increasing con-GSA-evoked current. Scale bars are shown left from each tracing. Ab-
centrations (indicated above the current tracings). Scale bars are shownbreviations are: Asp, l-aspartate; GBA, -guanidinobutyrate; G, guani-
on the top left. (B) Concentration-response relationship of spermine (Sp)dine; MG, methylguanidine; and APPA, 4-methyl APPA.
and spermidine (Spn) indicates the highest potency in spermine. Hill
plots have EC50s of 28 mmol/L and 68 mmol/L for spermine and sper-
midine, respectively. Mean inward currents and corresponding SEMs
(error bars) are from four cells (spermine) and seven cells (spermidine).
All cells were clamped at Vh 	60 mV.nidinoacetate were similar in magnitude to those evoked
by guanidinosuccinate, they displayed quite a different
aspect on the current tracings (Fig. 4A). It was also shown
that currents evoked by guanidinosuccinate were blocked mal current; Imax, the maximal current, and n, the Hill
by Mg2 or 4-methyl APPA (Fig. 4 B and C), whereas coefficient. For spermine-evoked currents (four cells),
those evoked by -guanidinopropionate or guanidi- the best fit was obtained with the following values (SE):
noacetate were not affected by these NMDA receptor EC50 	 28  8 mmol/L; Imax 	 423  36 pA; and n 	
antagonists (Fig. 4B). The polyamines spermine and sper- 1.02 0.23 (R 	 0.989); whereas for spermidine-evoked
midine evoked inward whole-cell currents with spermine currents (seven cells) these values were: EC50 	 68  41
as the most potent compound (Fig. 5). Both spermine mmol/L; Imax 	 427  96 pA; and n 	 0.97  0.29 (R 	
(Fig. 5A) and spermidine evoked inward whole-cell cur- 0.992).
rents, when applied in the millimolar concentration Application of 5 mmol/L spermine evoked a depolar-
range. Figure 5B shows the concentration-current curve izing current (Fig. 6A), which was not affected by appli-
of the spermine- and spermidine-evoked currents with cation of 500 mol/L Mg2, 10 mol/L 4-methyl APPA,
Hill equation: 100mol/L bicuculline, or [10mol/L 4-methyl APPA
10 mol/L CNQX] (Fig. 6B), indicating that it is notI 	 ImaxCn/(Cn  EC50n) mediated by ligand-gated channels of the GABAA,
with I, representing the mean current evoked by either AMPA, or NMDA type. Also, application of 10 mol/L
spermine or spermidine; C, the concentration of sper- ifenprodil, an antagonist at the polyamine site on the
NMDA receptor, did not block the spermine-evokedmine or spermidine; EC50, the concentration for half-maxi-
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Fig. 6. Depolarizing currents evoked by spermine, and effect of differ-
ent excitatory and inhibitory amino acid receptor antagonists. (A) A
neuron under current clamp depolarizes from 62 to 56 mV during
the application of 5 mmol/L spermine. (B) A typical recording shows
that spermine (Sp)-evoked whole-cell current was not affected by co-
application of any of the antagonists. Spermine was applied for 5 seconds
in a concentration of 5 mmol/L (indicated as horizontal bars above the
current tracings) to a cell clamped at Vh 	 60 mV. Scale bars are
shown on the top left. The five antagonists were studied at the following
concentrations: 500 mol/L Mg2; 10 mol/L 4-methyl APPA (APPA);
100 mol/L bicuculline (Bic); 10 mol/L 6-cyano-7-nitroquinoxaline-2,
3-dione (CNQX); and 10 mol/L ifenprodil (IFP).
current (Fig. 6B, bottom). Whereas the guanidinosucci-
nate-evoked current displayed a linear current-voltage re- Fig. 7. Current-voltage relationship of whole-cell current evoked by
5 mmol/L guanidinosuccinate (GSA) and 50 mmol/L spermine (Sp) inlationship with reversal potential around 0 mV (Fig. 7A),
a cell clamped at different potentials between 60 and 60 mV. (A)the current-voltage relationship of spermine-evoked in-
Guanidinosuccinate-evoked current typically displayed a linear current-
ward currents was nonlinear with maximal current at a voltage relationship with reversal potential around 0 mV. (B) The
current-voltage relationship of spermine-evoked inward currents washolding potential of 0 mV. Also, this latter current did
nonlinear with maximal current at a holding potential of 0 mV; thisnot reverse within the 60 to 60 mV range. Figure 7B
latter current did not reverse within the 60 to 60 mV interval. A
displays the effect of four different ion channel blockers typical recording shows the effect of ion channel blockers on the current
evoked by 5 mmol/L spermine. Spermine was applied for 5 seconds inon the spermine-evoked current. Only the Ca2 channel
a concentration of 5 mmol/L (indicated as horizontal bars above theblocker, Cd 2, appeared to have an effect on these cur- current tracings) to a cell clamped at Vh	60 mV. Only Cd2 appeared
rents, whereas K channels blockers like Ba2 or TEA to affect this current, whereas Ba2, Ni2 or tetraethylammonium (TEA)
had no effect. The following concentrations were used: 5 mmol/L Ba2;did not affect the spermine-evoked current.
5 mmol/L Ni2; 200 mol/L Cd2; and 10 mmol/L TEA.Spermine appeared to potentiate guanidinosuccinate-
evoked current. In Figure 8A it is shown that 1 mmol/L
guanidinosuccinate evokes an inward current of 257 pA
in amplitude, and 50 mmol/L spermine evokes an inward evoked current almost doubled (i.e., from 116 5% IASP
current of 685 pA. Applying the two compounds simu- to 206  11% IASP, P  0.001; Fig. 8B). In the presence
ltaneously evoked a current that was more than the sum of 10 mol/L ifenprodil, on the other hand, co-applica-
of the separate currents (1075 pA in Fig. 8A). Even at tion of spermine did not potentiate guanidinosuccinate-
concentrations that did not evoke any current as such, evoked current (Fig. 8B). More specifically, application
spermine potentiated guanidinosuccinate-evoked current of 10 mol/L ifenprodil decreased the Imax for guanidino-
(Fig. 8B). Concentration-current curves of guanidino- succinate-evoked current to 57.7  1.6% IASP (notably,
succinate-evoked current showed that in the presence without significantly changing the EC50). Co-application
of spermine now resulted in an Imax for guanidinosucci-of 100 mol/L spermine, Imax of the guanidinosuccinate-
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Fig. 8. Potentiation of guanidinosuccinate-evoked whole-cell current
by spermine. (A) A typical recording shows inward whole-cell currents
consecutively evoked by 1 mmol/L guanidinosuccinate (GSA), 50 mmol/L
spermine (Sp), and the co-application of both compounds. (B) The
amplitudes of these currents are 257 pA, 685 pA, and 1075 pA, respec-
tively. Concentration-current curves of GSA with or without 100mol/L
or 5 mmol/L spermine illustrates the increase of the Imax for GSA-evoked
currents by spermine. Co-application of spermine at a concentration that
does not evoke current as such (100 mol/L) potentiates GSA-evoked
current (left graph). Imax for GSA-evoked current without spermine ()
almost doubles in the presence of spermine (). This increase in Imax
was antagonized by the co-application of 10 mol/L ifenprodil (left
graph). In the presence of ifenprodil, Imax for current evoked by GSA
alone () was actually somewhat lower than that for current evoked
Fig. 9. Dose-response curves for the induction of minimal generalizedby GSA with 100 mol/L spermine (). A high concentration of sper-
clonic seizures (stage 1, A) and full-blown clonic seizures with loss ofmine (5 mmol/L) evoked an inward ifenprodil-insensitive whole-cell
righting reflex (stage 2, B) following intraperitoneal administration ofcurrent, and also potentiated GSA-evoked current (right graph). All
guanidinosuccinate (GSA), with or without prior intracerebroventricu-cells were clamped at 60 mV.
lar injection of 0.25 mol spermine () and (), respectively. Median
convulsive doses of GSA (CD50), and their 95% confidence intervals,
required for the induction of stage 1 (A) or stage 2 (B) seizures, are
indicated centrally in both figures. *P  0.05 (statistical significance of
nate-evoked current of 47.5  2.3% IASP. Co-application differences between CD50 values); **P  0.01 (statistical significance
of differences between CD50 values). Ten mice were used for each doseof guanidinosuccinate and a high concentration of sper-
of GSA.mine (5 mmol/L) potentiated guanidinosuccinate-evoked
current in a non-additive fashion (Fig. 8B). Ifenprodil-
insensitive currents evoked by high (millimolar) concen-
trations of spermine were additive with the current ing vigor in animals injected with the highest doses of
evoked by guanidinosuccinate. guanidinosuccinate. This could lead to a severe status of
clonic seizures with rolling, clonic jerking and twisting
Convulsions evoked by guanidinosuccinate of body and limbs, grasping or clawing with fore- and
and spermine hindpaws, hypersalivation, and vocalization (stage 2 sei-
Systemic (intraperitoneal) injection of guanidinosucci- zures). This clonic status would end in some of the ani-
nate in mice evoked clonic seizures in a dose-dependent mals with tonic extension of the limbs. Stage 1 seizures
fashion (Fig. 9). Typically, mice started to show signs of were evoked with a CD50 (and 95% confidence interval)
agitation and myoclonic jerking 10 to 15 minutes after of 7.08 (5.89 to 8.50) mmol/kg, and stage 2 seizures with
injection. Approximately 15 minutes after injection, the a CD50 of 8.12 (7.24 to 9.12) mmol/kg (Fig. 9).
animals displayed jumping and running fits and clonic Mice injected intracerebroventricularly with 0.5 mol
contractions of limb and body muscles (stage 1 seizures). spermine (N 	 3) displayed signs of agitation, clonic
movements of the limbs, myoclonic jerking of the body,Clonic movements and running fits occurred with increas-
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and rolling. These behavioral signs, which were rather are increased in the blood of uremic patients, but concen-
trations in uremic brain are not available for these com-benign and distinctly different from the much more vigor-
ous guanidinosuccinate-evoked seizures, occurred within pounds. Several indolic tryptophan metabolites are in-
creased in uremic serum and muscle [24, 25]. Indolesa few minutes after injection. On the other hand, no
clonic seizures were observed in any of the mice injected may be responsible for the reduction in drug-protein
binding observed in uremia [26, 27]. Hida et al [28] foundwith 0.25 mol spermine (N  50), although several ani-
mals did show signs of agitation. The guanidinosuccinate indole metabolites to be almost 100-fold increased in
uremic serum with low reduction rates after hemodialy-dose-response curves for the induction of stage 1 and
stage 2 seizures were shifted to the left in animals injected sis. As well, phenol and especially p-cresol are highly in-
creased in uremic plasma [28–30] with some authors re-intracerebroventricularly with 0.25mol spermine prior to
guanidinosuccinate injection (Fig. 9). In such spermine- porting concentrations for p-cresol as high as 248mol/L
[31]. Phenols are also poorly eliminated by current meth-pretreated mice, stage 1 and stage 2 seizures were evoked
with a CD50 (and 95% confidence interval) of 3.92 (3.39 ods of extracorporeal solute removal, and their suspected
role as major uremic toxins has received quite someto 4.54) mmol/kg and 4.45 (3.78 to 5.25) mmol/kg, respec-
tively. These values were significantly lower than those attention in recent years [31].
However, in view of the lack of information aboutobserved in mice without spermine-pretreatment (Fig. 9).
uremic brain concentrations, we will have to be especially
cautious when proposing a role for these latter com-
DISCUSSION
pounds in uremic encephalopathy and other neurologic
Seventeen uremic retention solutes were tested for complications of uremia. Indoles have been suggested
their effects on voltage-clamped mouse spinal cord neu- to increase the progression of glomerular sclerosis [32],
rons using the tight-seal whole-cell recording technique. but a role in uremic encephalopathy has not been pro-
The aim of this study was to identify solutes with poten- posed. Notably, however, serum concentrations of tryp-
tial neurotoxicity and to propose potential mechanisms tophan and indole-3-acetate correlated with the degree
of action. It was shown that four of the compounds tested of cognitive impairment in cirrhotic patients [33]. Indoles
evoked significant whole-cell currents under the present like 3-indoxyl sulfate could be transported into the brain
experimental conditions, namely, 3-indoxyl sulfate, gua- by the organic anion transporter (OAT3), and thus accu-
nidinosuccinate, spermine, and phenol. The three former mulate [34]. These indoles (most markedly 3-indoxyl
compounds evoked inward whole-cell currents, whereas sulfate) were presently shown to evoke inward whole-
phenol evoked an outward current. It is tempting to cell current, which was not inhibited by any of the ligand-
speculate that depolarizing, inward currents, possibly in or voltage-gated ion channel blockers used here, and
combination with other excitatory effects of various ure- appears to be due to various ionic conductances. The
mic toxins, could underlie the increased excitability in attenuation of the indole-evoked current by Ba2 and
uremic brain. In addition, it was shown that guanidino- Cd 2 indicates the (partial) involvement of voltage-gated
succinate and spermine both induced convulsions in Ca2 channels.
mice, and that spermine potentiated the convulsive effect Phenol and p-cresol, on the other hand, evoked out-
of guanidinosuccinate. The results presented in this study ward whole-cell current, which was reversed by antago-
clearly demonstrate neuroexcitatory and synergistic ef- nists at voltage-gated K channels. The present find-
fects in these compounds, which might be important to ings confirm that phenol does not directly interact with
the understanding and treatment of uremic encephalopa- membrane Ca2 channels. It has been suggested that
thy and other neurologic complications of renal failure. phenols may have a biphasic effect with low concentra-
Urea was chosen as a reference compound and did tions (1 mmol/L) increasing, and high concentrations
not appear to evoke whole-cell current in its presently ap- (1 mmol/L) decreasing nerve and muscle excitability
plied concentration. Although it is a clear indicator of [35]. In vivo, phenol and p-cresol provoked epileptic
renal failure, urea may not actually play an important seizures in rats and mice [36, 37], and phenol facilitated
role in uremic encephalopathy, and encephalopathic neuromuscular transmission in cats [38]. The mechanism
manifestations have been known to improve, notwith- of phenol-evoked changes in nerve and muscle excitabil-
standing the persistence of high urea concentrations [4]. ity is not entirely clear, but may be due to alterations in
Compared against urea, significant whole-cell currents membrane permeability and specific interactions with
were evoked by 3-indoxyl sulfate, phenol, guanidinosuc- voltage-gated K channels [31, 35, 39]. The activation
cinate, and spermine in voltage-clamped spinal cord neu- of voltage-gated K channels may at least partly explain
rons. Each of these compounds is increased in uremia the presently observed phenol-evoked outward current.
and has been proposed as a putative uremic toxin [11, The other two uremic retention solutes, spermine and
13, 22, 23]. guanidinosuccinate, evoked inward whole-cell currents
at their putative pathologic brain concentrations andEvidence indicates that 3-indoxyl sulfate and phenol
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demonstrated specific neuroexcitatory and synergistic bral cortex compared to subcortical structures with con-
centrations in white matter of about twice those in grayfeatures. In support of the Ca2 toxity hypothesis, the
currents evoked by spermine and guanidinosuccinate ap- matter [50]. White matter concentrations of spermine as
high as 920 nmol/g tissue (spermidine, 320 nmol/g tissue)peared to be due to specific interaction with voltage- and
ligand-gated Ca2 channels. Guanidinosuccinate-evoked were reported in one normal individual [50], suggesting
that extracellular polyamine concentrations in normalcurrent was completely blocked by NMDA receptor an-
tagonists. This observation is in accordance with our brain could be in the micromolar or low millimolar range.
Anderson, Crossland, and Shaw [52] reported that evenprevious identification of this compound as an endoge-
nous NMDA receptor agonist acting at the neurotrans- low doses of intracerebroventricularly injected spermine
(10 g) could produce hyperexcitability and convulsionsmitter binding site of the receptor [40]. We observed
presently that the current evoked by guanidinosuccinate in mice, whereas spermidine was considerably less po-
tent. Apart from behavioral signs of neuroexcitation andwas potentiated by possibly (patho)physiologic brain
concentrations of spermine. This suggests that increased neurotoxicity reported here and elsewhere, intracerebro-
ventricular injection of spermine or spermidine in miceconcentrations of these compounds in uremic brain could
actually have synergistic neuroexcitatory effects. and rabbits produced a pattern of characteristic focal
encephalomalacic lesions as well [52].Several guanidino compounds were highly increased
in uremic fluids and tissues [41, 42]. Notably in cerebro- A dual mechanism appears to be involved in the neu-
roexcitatory effect of these polyamines. Inward currentspinal fluid of uremic patients, guanidinosuccinate con-
centrations in excess of 30 mol/L have been reported evoked by high (millimolar) concentrations of spermine
appeared to be due to direct activation of voltage-gated[41]. Guanidinosuccinate is an aspartate analog and an
NMDA receptor agonist [40]. Guanidinosuccinate and Ca2 channels. When applied in the millimolar range,
the polyamines spermine and (somewhat less potently)other uremic guanidino compounds were also shown to
block GABAA receptors [43, 44]. Particularly in the case spermidine evoked depolarizing inward currents, which
were not antagonized by excitatory or inhibitory aminoof guanidinosuccinate, these and other neuroexcitatory
effects were found at concentrations similar to those acid receptor antagonists. These observations as well as
the typical nonlinear current-voltage relationship andfound in uremic brain, and guanidino compounds were
consequently proposed as uremic neurotoxins with major the antagonistic effect of Cd2 indicated that these cur-
rents were caused by the activation of voltage-gated Ca2importance in the pathophysiology of uremic encepha-
lopathy [45]. channels. Preliminary observations by Scott, Sutton, and
Dolphin [53] indicated that spermine enhanced Ca2 cur-The polyamines spermine and spermidine were pro-
posed to contribute to various aspects of the uremic rents in cultured dorsal root ganglion cells, and several
other authors have reported neuroexcitatory effects ofsyndrome [46]. However, there is some debate about the
actual serum or plasma levels of these polyamines in polyamines that appeared not to be mediated by the
NMDA receptor-associated polyamine site. For exam-controls and uremic patients as well as about their bind-
ing to proteins. Campbell [46] suggested that their serum ple, Bourdiol et al [54] reported neuronal cell loss and
other neurotoxic effects of intrastriatal injection ofand plasma concentrations, normally in the low micro-
molar range, may be increased two to five times in uremic spermine which were insensitive to pretreatment with the
NMDA antagonist dizocilpine. Intracerebroventricularpatients, but this finding was later challenged by Spragg,
Bentley, and Coles [47]. These latter authors used liquid injection of spermine not only caused neurotoxic effects
in hippocampus and other brain regions, but was alsochromatography with precolumn derivatization instead
of radioimmunoassay and measured about 10 times shown to impair subsequent spatial learning [55]. These
behavioral effects of spermine injection were also foundlower levels compared to those previously reported by
Campbell et al [48]. They also found no difference be- to be insensitive to dizocilpine treatment. Possibly, such
effects are due to activation of voltage-gated Ca2 chan-tween patients and controls, whereas Saito et al [49],
using liquid chromatography with postcolumn derivati- nels as polyamines were shown to interact directly as well
as indirectly with these and other cation channels [53].zation, found similar control levels as Spragg, Bentley,
and Coles [47], but levels in predialysis patients were Spermine concentrations below 1 mmol/L, on the
other hand, did not affect our voltage-clamped cells, butfound to be several times increased.
The actual uremic brain concentrations of these poly- such concentrations did potentiate the inward current
evoked by guanidinosuccinate. This potentiating effectamines could still be debated, but evidence indicates that
even slight increases in their concentration could affect was antagonized by ifenprodil, an antagonist at the
NMDA receptor-associated polyamine binding site [56].brain physiology. Normal brain concentrations as high
as 100 to 300 nmol/g tissue were reported for these com- In the present study, low (micromolar) concentrations
of spermine potentiated guanidinosuccinate-evoked cur-pounds in rats and mice [50, 51]. In human brain, sper-
mine and spermidine concentrations were highest in cere- rent through the action of spermine on the polyamine
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binding site of the NMDA receptor. Mainly due to the other hand, showed that the changes in red blood cells
are not likely to be due to increased PTH levels, butproposed role of the NMDA receptor in many physio-
logic and pathophysiologic processes, the action of poly- rather to fast-acting and much smaller molecules. As our
findings indicated, increased levels of indoles, guanidinoamines on this neuroreceptor has been studied exten-
sively [57]. Spermine and spermidine were shown to compounds, or polyamines could also contribute to in-
creased intracellular Ca2 concentrations in uremic braininteract with a specific polyamine binding site, and en-
hance NMDA receptor-mediated currents by increasing through their interaction with voltage- or ligand-gated
Ca2 channels. These small molecules appear to be ablethe opening frequency of the NMDA receptor-associ-
ated ion channel [57, 58]. to activate Ca2 channels directly, and may add to the
effects of PTH and other putative uremic toxins to in-Finally, both spermine and guanidinosuccinate dis-
played neuroexcitatory effects in vivo. Systemic adminis- crease intracellular Ca2 in uremic brain.
tration of spermine and spermidine induces several neu-
roexcitatory effects in rats and mice [59]. Systemic and CONCLUSION
intracerebral administration of guanidinosuccinate in-
Four out of 17 candidate uremic neurotoxins examinedduces clonic and tonic convulsions in mice [19]. The
(i.e., 3-indoxyl sulfate, guanidinosuccinate, spermine, andpresent findings show that intracerebroventricular ad-
phenol) evoked significant whole-cell currents on mouseministration of spermine potentiates the convulsions in-
spinal cord neurons in primary dissociated cell culture.duced by guanidinosuccinate, which may again be due
Inward whole-cell current evoked by 3-indoxyl sulfateto agonistic effects of both compounds on NMDA recep-
was not blocked by any of the applied ligand- or voltage-tors. Using similar procedures, Singh, Oles, and Wood-
gated ion channel blockers, and the compound appearedruff [60] found that intracerebroventricular spermidine
to influence various membrane ionic conductances (prob-decreased seizure latency as well as the dose of N-methyl-
ably also including voltage-gated Ca2 channels). Phenoldl-aspartate required to induce convulsions in mice.
evoked outward whole-cell currents that were at leastThese effects were not due to some general proconvul-
partly due to the activation of voltage-gated K channels,sive effect of spermidine since pentylenetetrazol-induced
but also appeared to involve a variety of other ionic con-seizures were not potentiated in this protocol. Examin-
ductances. On the other hand, inward whole-cell currentsing in vivo neuroexcitation following intracerebroven-
evoked by guanidinosuccinate and spermine were showntricular administration of spermine, Doyle and Shaw
to be due to specific interaction with voltage-gated Ca2[61, 62] identified two distinct phases in the spermine-
channels and the NMDA receptor ion channel complex.induced effects, which were due to different pharmaco-
Spermine potentiated guanidinosuccinate-evoked inwardlogic mechanisms.
current as well as clonic convulsions induced by this com-By and large, these and other findings indicate that bio-
pound. Although renal insufficiency leads to the accumu-chemical alterations associated with the uremic state pro-
lation of a large number of uremic retention solutes infoundly affect various neurophysiologically important
biologic fluids and tissues, the available evidence suggestsionic equilibria. For example, veratridine-stimulated Na
that guanidinosuccinate and spermine are among the mostuptake was increased in synaptosomes from uremic rats,
likely candidates to play leading roles in the neurologicwhich was probably due to alterations in Na-K-
complications of renal failure.ATPase pump activity [63]. However, some authors have
viewed chronic renal failure as primarily a state of cellu- ACKNOWLEDGMENTS
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